GlassScriptPhysician profile
Khaled M Nazzal
NPI 1881859726
$549.93
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $502 · 2020: $47.95.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $134.39 | 2019 | |
| Genentech USA, INC. | $122.84 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.09 | 2019 | |
| Sunovion Pharmaceuticals INC. | $41.61 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $37.92 | 2019 | |
| Grifols USA, LLC | $33.89 | 2019 | |
| Merck Sharp & Dohme LLC | $25.81 | 2019 | |
| Shire North American Group INC | $23.15 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $20.99 | 2019 | |
| Philips North America LLC | $19.07 | 2019 | |
| Novartis Pharmaceuticals Corporation | $17.41 | 2019 | |
| Gilead Sciences, INC. | $14.90 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.86 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khaled Nazzal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.